GlassScriptPhysician profile
Rita Carabello
NPI 1952346983
$16,466.50
in general payments reported to CMS, 2019-2025
47 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,286 · 2020: $3,583 · 2021: $4,310 · 2022: $3,336 · 2023: $1,722 · 2024: $78.64 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,756.40 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Novo Nordisk INC | $1,741.35 | 2019-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $1,552.56 | 2019-2024 | Trelegy Ellipta |
| Abbvie INC. | $1,441.61 | 2021-2023 | Vraylar, Ubrelvy, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,016.43 | 2019-2023 | Xifaxan |
| Amarin Pharma, INC. | $918.37 | 2019-2022 | |
| Lilly USA, LLC | $862.33 | 2019-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $719.94 | 2019-2022 | |
| Gilead Sciences, INC. | $694.66 | 2019-2023 | |
| Pfizer INC. | $633.64 | 2019-2023 | |
| Astellas Pharma US INC | $588.95 | 2019-2023 | Myrbetriq |
| Allergan, INC. | $497.30 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.70 | 2019-2023 | Synjardy, Jardiance, Tradjenta |
| Neurocrine Biosciences, INC. | $392.88 | 2019-2023 | Ingrezza |
| Amgen INC. | $381.83 | 2019-2023 | Otezla, Repatha |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Carabello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.